12:00 AM
Mar 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Alisertib: Phase III started

Takeda's Millennium Pharmaceuticals Inc. subsidiary began an open-label, international Phase III trial to compare oral alisertib twice daily for first 7 days of a 21-day cycle vs. single agent...

Read the full 132 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >